Guggenheim Capital LLC Biogen Inc. Transaction History

Guggenheim Capital LLC

$13.9 Billion
Q2 2024

A detailed history of Guggenheim Capital LLC transactions in Biogen Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 62,343 shares of BIIB stock, worth $10.8 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

62,343

Previous 69,050 9.71%

Holding current value

$10.8 Million

Previous $14.9 Million 2.94%

% of portfolio

0.1%

Previous 0.11%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $1.28 Million - $1.59 Million	-6,707 Reduced 9.71%	62,343 $14.5 Million
Q1 2024 May 14, 2024	BUY	$212.02 - $267.71 $210,959 - $266,371	995 Added 1.46%	69,050 $14.9 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $101,723 - $122,448	-457 Reduced 0.67%	68,055 $17.6 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $1.92 Million - $2.17 Million	7,593 Added 12.46%	68,512 $17.6 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $953,190 - $1.1 Million	3,463 Added 6.03%	60,919 $17.4 Million
Q1 2023 May 10, 2023	SELL	$256.56 - $292.34 $533,901 - $608,359	-2,081 Reduced 3.5%	57,456 $16 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $951,698 - $1.16 Million	-3,770 Reduced 5.96%	59,537 $16.5 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $1.75 Million - $2.41 Million	-8,969 Reduced 12.41%	63,307 $16.9 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $1.67 Million - $1.99 Million	-8,909 Reduced 10.97%	72,276 $14.7 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $1.47 Million - $1.85 Million	-7,595 Reduced 8.55%	81,185 $17.1 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $2.26 Million - $2.91 Million	10,109 Added 12.85%	88,780 $21.3 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $896,229 - $1.17 Million	-3,167 Reduced 3.87%	78,671 $22.3 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $528,101 - $845,593	2,039 Added 2.56%	81,838 $28.3 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $3.61 Million - $4.23 Million	-14,870 Reduced 15.71%	79,799 $22.3 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $1.58 Million - $2.38 Million	-6,702 Reduced 6.61%	94,669 $23.2 Million
Q3 2020 Nov 13, 2020	SELL	$264.77 - $305.71 $4.16 Million - $4.81 Million	-15,720 Reduced 13.43%	101,371 $28.8 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $3.33 Million - $4.41 Million	12,871 Added 12.35%	117,091 $31.3 Million
Q1 2020 Jun 02, 2020	SELL	$268.85 - $341.04 $10.7 Million - $13.6 Million	-39,975 Reduced 27.72%	104,220 $33 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $2.67 Million - $3.69 Million	-12,140 Reduced 7.77%	144,195 $42.8 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $4.34 Million - $4.87 Million	-19,979 Reduced 11.33%	156,335 $36.4 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $202,843 - $223,591	925 Added 0.53%	176,314 $41.2 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $4.16 Million - $6.5 Million	19,183 Added 12.28%	175,389 $41.5 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $123,654 - $156,621	444 Added 0.29%	156,206 $47 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $4.51 Million - $5.9 Million	-15,365 Reduced 8.98%	155,762 $55 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $38.5 Million - $45.9 Million	-149,505 Reduced 46.63%	171,127 $49.7 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $10.2 Million - $14.4 Million	39,127 Added 13.9%	320,632 $87.8 Million
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $17.7 Million - $19.8 Million	-57,580 Reduced 16.98%	281,505 $89.7 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $95.3 Million - $112 Million	339,085	339,085 $106 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Biogen Inc. Transaction History